Literature DB >> 11478785

Preconditioning decreases ischemia/reperfusion-induced peroxynitrite formation.

C Csonka1, T Csont, A Onody, P Ferdinandy.   

Abstract

The role for peroxynitrite (ONOO(-)) in the mechanism of preconditioning is not known. Therefore, we studied effects of preconditioning and subsequent ischemia/reperfusion on myocardial ONOO(-) formation in isolated rat hearts. Hearts were subjected to a preconditioning protocol (three intermittent periods of global ischemia/reperfusion of 5 min duration each) followed by a test ischemia/reperfusion (30 min global ischemia and 15 min reperfusion). When compared to nonpreconditioned controls, preceding preconditioning improved postischemic cardiac performance and significantly decreased test ischemia/reperfusion-induced formation of free nitrotyrosine measured in the perfusate as a marker for cardiac endogenous ONOO(-) formation. During preconditioning, however, the first period of ischemia/reperfusion increased nitrotyrosine formation, which was attenuated after the third period of ischemia/reperfusion. We conclude that classic preconditioning inhibits ischemia/reperfusion-induced cardiac formation of ONOO(-) and that subsequent periods of ischemia/reperfusion result in a gradual attenuation of ischemia/reperfusion-induced ONOO(-) generation. This mechanism might be involved in ischemic adaptation of the heart. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478785     DOI: 10.1006/bbrc.2001.5308

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

Review 1.  Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.

Authors:  György Dormán; Sándor Cseh; István Hajdú; László Barna; Dénes Kónya; Krisztina Kupai; László Kovács; Péter Ferdinandy
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

2.  Peroxynitrite: just an oxidative/nitrosative stressor or a physiological regulator as well?

Authors:  Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

3.  Rapid ventricular pacing-induced postconditioning attenuates reperfusion injury: effects on peroxynitrite, RISK and SAFE pathways.

Authors:  Márton Pipicz; Zoltán V Varga; Krisztina Kupai; Renáta Gáspár; Gabriella F Kocsis; Csaba Csonka; Tamás Csont
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

4.  Late phase ischemic preconditioning preserves mitochondrial oxygen metabolism and attenuates post-ischemic myocardial tissue hyperoxygenation.

Authors:  Yuanjing Li; Ming Cai; Yi Xu; Harold M Swartz; Guanglong He
Journal:  Life Sci       Date:  2010-11-02       Impact factor: 5.037

Review 5.  Nitrite in organ protection.

Authors:  Tienush Rassaf; Peter Ferdinandy; Rainer Schulz
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 6.  Cardiac NO signalling in the metabolic syndrome.

Authors:  O Pechánová; Z V Varga; M Cebová; Z Giricz; P Pacher; P Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

7.  Adrenomedullin acts via nitric oxide and peroxynitrite to protect against myocardial ischaemia-induced arrhythmias in anaesthetized rats.

Authors:  Yee Hoo Looi; Kathleen A Kane; Allan R McPhaden; Cherry L Wainwright
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

Review 8.  Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning.

Authors:  Péter Ferdinandy; Richard Schulz
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

Review 9.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

10.  Peroxynitrite decreases arrhythmias induced by ischaemia reperfusion in anaesthetized dogs, without involving mitochondrial KATP channels.

Authors:  A Kiss; L Juhász; I Huliák; A Végh
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.